Basic Information
Trevi Therapeutics is a clinical-stage biopharmaceutical company developing treatments for uremic pruritus. Trevi is currently developing nalbuphine ER for the treatment of chronic pruritus and chronic cough in patients with idiopathic pulmonary fibrosis (IPF), as well as levodopa-induced dyskinesia (LID) in patients with Parkinson's disease.
Trevi Therapeutics, Inc.
NewHaven,Connecticut,United States of America
15~50 people
March 17, 2011
mediarelations@trevitherapeutics.com
Enterprise Profile
Industrial Sector
Concept
Application Scenarios